Wednesday, October, 16, 2019 08:51:12

Contribution By Shikha Sinha


GlaxoSmithKline Plc receives U.S FDA approval for HIV drug Dovato

One of the world’s leading pharma company GlaxoSmithKline Plc has reportedly attained the approval of the U.S. FDA for marketing its two-drug treatment for HIV infections, thereby boosting its growth prospects against rival Gilead Sciences Inc. As per trusted sources, the U.S. FDA cleared Dovato, …

Novacyt, Immunexpress expand contract for developing diagnostic assays

The partnership expansion would further support the development of rapid diagnostic assays needed for detecting sepsis Novacyt, a global clinical diagnostics specialist, has recently announced that Primerdesign Ltd, its molecular testing division, has expanded its assay development contract with Immunexpress, Inc., a molecular diagnostic company …

Aeglea presents positive data for Pegzilarginase to treat ARG1-D

The clinical-stage biotechnology company, Aeglea BioTherapeutics Inc., has reportedly announced positive Phase 1/2 data for Pegzilarginase to be used in the treatment of patients with ARG1-D (Arginase 1 Deficiency). Dr. George Diaz, Ph.D., M.D., Division Chief of Medical Genetics, Icahn School of Medicine, New York, …

Viking Therapeutics to present data from Phase 2 study of VK2809

Clinical-stage biopharmaceutical company Viking Therapeutics, Inc. will reportedly present data from its 12-week long Phase 2 trial of VK2809 on individuals suffering from non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol at the International Liver Congress™ 2019. According to familiar sources, the study results …

Cellgen, GTC unite to develop companion tests for cancer therapies

The two firms will focus on accelerating global development of companion tests for several oncology therapies. Renowned precision diagnostics firm, Cellgen Diagnostics has recently announced a strategic collaboration with Genomic Testing Cooperative (GTC) to help accelerate global development of companion tests for various oncology therapeutics. …

Sangamo & Pfizer unveil data from gene therapy for severe hemophilia A

More than eight individuals treated with the SB-525 gene therapy demonstrated increases in FVIII activity that was dose-dependent. The FVIII levels reached normal in two patients that were treated with a 3e13 vg/kg dose. Sangamo Therapeutics, Inc., (Sangamo), a California-based biotechnology company, and New York-based …

Medical wearable start-up Ten3T raises funding from ITI Growth Fund

ten3T will reportedly use the funds to expand the usability of their product called Cicer for ambulance monitoring, pharmacovigilance studies and homes. ten3T Healthcare Pvt. Ltd, a Bengaluru based medical wearable device startup, has reportedly raised an unrevealed amount in a pre-Series A funding round. …